{{Rsnum
|rsid=3732183
|Gene=MSH2
|Chromosome=2
|position=47466820
|Orientation=plus
|GMAF=0.4669
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=MSH2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 12.5 | 36.6 | 50.9
| HCB | 40.7 | 45.2 | 14.1
| JPT | 31.2 | 55.4 | 13.4
| YRI | 54.4 | 38.8 | 6.8
| ASW | 32.1 | 55.4 | 12.5
| CHB | 40.7 | 45.2 | 14.1
| CHD | 45.4 | 42.6 | 12.0
| GIH | 7.9 | 44.6 | 47.5
| LWK | 41.3 | 50.5 | 8.3
| MEX | 8.6 | 36.2 | 55.2
| MKK | 50.0 | 39.7 | 10.3
| TSI | 6.9 | 34.7 | 58.4
| HapMapRevision=28
}}{{PMID Auto
|PMID=20091185
|Title=MGMT -535G&gt;T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy
}}

{{ClinVar
|rsid=3732183
|Reversed=0
|FwdREF=G
|FwdALT=A
|REF=G
|ALT=A
|RSPOS=47693959
|CHROM=2
|GMAF=0.4666
|dbSNPBuildID=107
|SSR=0
|SAO=1
|VP=0x05016800000017051f100100
|GENEINFO=MSH2:4436
|GENE_NAME=MSH2
|GENE_ID=4436
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000002.11:g.47693959G>A
|CLNSRC=InSiGHT
|CLNORIGIN=1
|CLNSIG=2
|CLNDBN=Lynch syndrome; AllHighlyPenetrant
|Disease=Lynch syndrome; AllHighlyPenetrant
|Tags=PM;PMC;SLO;VLD;G5A;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD
|CAF=0.5331; 0.4669
|CLNACC=RCV000030241.2; RCV000035358.2
|CLNDSDB=GeneReviews:MedGen:SNOMED_CT; MedGen
|CLNDSDBID=NBK1211:C0009405:315058005; CN169374
|COMMON=1
|CLNSRCID=c.1661+12G>A
}}

{{PMID Auto
|PMID=19930554
|Title=Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}